Identifiable genetic causes explain approximately 40% of familial dilated cardiomyopathy cases, influencing arrhythmia and sudden cardiac death risk.
This review highlights the growing role of molecular genetics in identifying familial dilated cardiomyopathy and the potential for gene mechanism-specific therapies.
Absolute Event Rate: 0% vs 0%
Dilated cardiomyopathy (DCM) is defined as dilation and/or reduced function of one or both ventricles and remains a common disease worldwide. An estimated 40% of cases of familial DCM have an identifiable genetic cause. Accordingly, there is a fast-growing interest in the field of molecular genetics as it pertains to DCM. Many gene mutations have been identified that contribute to phenotypically significant cardiomyopathy. DCM genes can affect a variety of cardiomyocyte functions, and particular genes whose function affects the cell–cell junction and cytoskeleton are associated with increased risk of arrhythmias and sudden cardiac death. Through advancements in next-generation sequencing and cardiac imaging, identification of genetic DCM has improved over the past couple decades, and precision medicine is now at the forefront of treatment for these patients and their families. In addition to standard treatment of heart failure and prevention of arrhythmias and sudden cardiac death, patients with genetic cardiomyopathy stand to benefit from gene mechanism–specific therapies.
Eldemire et al. (Tue,) reported a other. Identifiable genetic causes explain approximately 40% of familial dilated cardiomyopathy cases, influencing arrhythmia and sudden cardiac death risk.